NCT04830449

Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients

A Multi-center, Randomized, Double-blinded, Active-Controlled, Parallel, Phase III Study to Evaluate the Efficacy and Safety of HCP1904-2 in Essential Hypertension Patients.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 122 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate of efficacy and safety of HCP1904-2 and RLD2001-2 alone in patients with essential hypertension inadequately controlled on RLD2001-2 monotherapy.

Detailed description

A Multi-center, Randomized, Double-blinded, Active-controlled, Parallel, Phse III Study to Evaluate the Efficacy and Safety of HCP1904-2 in Essential Hypertension Patients

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	HCP1904-2	Take it once daily for 8 weeks orally.
DRUG	RLD2001-2	Take it once daily for 8 weeks orally.

Timeline

• Start date: 2020-10-29
• Primary completion: 2021-08-24
• Completion: 2021-08-24
• First posted: 2021-04-05
• Last updated: 2023-09-22

Locations

1 site across 1 country: South Korea